イスラエル - 英語 - Ministry of Health

novartis israel ltd - glycopyrronium as bromide - inhalation powder hard capsules - glycopyrronium as bromide 50 mcg - glycopyrronium - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

イスラエル - 英語 - Ministry of Health

novartis israel ltd - onasemnogene abeparvovec - suspension - onasemnogene abeparvovec 2 x 10^13 vg / 1 ml - onasemnogene abeparvovec - zolgensma is indicated for the treatment of:- patients with 5q spinal muscular atrophy (sma) with a bi-allelic mutation in the smn1 gene and a clinical diagnosis of sma type 1, or- patients with 5q sma with a bi-allelic mutation in the smn1 gene and up to 3 copies of the smn2 gene.

南アフリカ - 英語 - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - diluent for injection - see ingredients - each ampoule contains water for injections 5ml or 10 ml

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - drugs for obstructive airway diseases, - allergic asthmaxolair is indicated in adults, adolescents and children (6 to

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older.it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid modifying agents - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multiple sclerosis, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.1).

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis europharm limited - canakinumab - cryopyrin-associated periodic syndromes; arthritis, juvenile rheumatoid; arthritis, gouty - interleukin inhibitors, - periodic fever syndromesilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:cryopyrin-associated periodic syndromesilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) including:muckle-wells syndrome (mws),neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca),severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.tumour necrosis factor receptor associated periodic syndrome (traps)ilaris is indicated for the treatment of tumour necrosis factor (tnf) receptor associated periodic syndrome (traps).hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd)ilaris is indicated for the treatment of hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd).familial mediterranean fever (fmf)ilaris is indicated for the treatment of familial mediterranean fever (fmf). ilaris should be given in combination with colchicine, if appropriate.ilaris is also indicated for the treatment of:still’s diseaseilaris is indicated for the treatment of active still’s disease including adult-onset still’s disease (aosd) and systemic juvenile idiopathic arthritis (sjia) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (nsaids) and systemic corticosteroids. ilaris can be given as monotherapy or in combination with methotrexate.gouty arthritisilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.